Adaptimmune is a Cambridge-based company dedicated to revolutionizing the treatment of solid tumor cancers. Utilizing a proprietary cell therapy platform, they engineer a patient's own cells to combat their cancer, offering a personalized approach that has the potential to significantly improve the patient experience.
With their first Biologics License Application (BLA) submitted to the FDA, Adaptimmune is on the cusp of a new era in cancer treatment. Their goal is to commercialize the first engineered T-cell therapy for solid tumors, aiming to reshape the landscape of cancer care with a single infusion.
Generated from the website